Hostname: page-component-848d4c4894-jbqgn Total loading time: 0 Render date: 2024-06-30T21:43:00.113Z Has data issue: false hasContentIssue false

Workshop I: Evidence-informed approach to prescribing of atypical antipsychotics to manage behaviors in Neurocognitive disorders: Results of a pilot study

Published online by Cambridge University Press:  02 February 2024

Atul Sunny Luthra
Affiliation:
Medical Coordinator, Program for Older Adults, Homewood Health Centre 150 Delhi Street, Guelph, Ontario, Canada, N1E 6K9, (519)824-1010 ext. 2241 [email protected]
Raymond LinBin Gao
Affiliation:
Pharmacological Department Clinical pharmacist, Ontario, Canada
Peter Carducci
Affiliation:
University of Waterloo, School of Pharmacy, Waterloo, Ontario, Canada
Joanna Sue
Affiliation:
Clinical Neuropsychologist, Hamilton, Ontario, Canada
Shannon Remers
Affiliation:
Guelph, Ontario, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The LuBAIR™ Paradigm is a novel approach to ascribe meaning to behavioral expressions in advanced neurocognitive disorders when the reliability of a clinical assessment is limited. The meaning ascribed to each behavioral category was used to identify those who are likely to respond to the use of atypical antipsychotics in their management. De-prescribing was attempted on patients who qualified to enter this retrospective study. De-prescribing was defined as successful if individuals were completely withdrawn from AAP and remained off them for 60 days without the re-emergence of behaviors.

Methods:

The LuBAIR™ Inventory was filled on two occasions. The data collected on the second occasion, in the successful and failed de-prescribed groups, were compared in this retrospective study. MANOVA, Chi-Square paired t-test statistical analyses were used to detect the differences in the behavioral categories between the two cohorts. Cohen d was used to measure effect size.

Results:

Patients who did not have Mis-Identification and Goal-Directed Expressions were more likely to successfully de-prescribe: X2 (1, N = 40) = 29.119 p < 0.0001 and X2 (1, N = 40) = 32.374, p < 0.0001, respectively. Alternatively, the same behavioral categories were more likely to be present in patients who failed de-prescribing: MANOVA and paired t-test (p < 0.0001).

Conclusion:

Atypical antipsychotics, in their role as an antipsychotic and mood stabilizer, may be used to manage Mis-Identification and Goal-Directed Expressions, respectively.

Type
Pre Congress Workshops
Copyright
© International Psychogeriatric Association 2024

Footnotes

The senior author would like to thank Murray Alzheimer’s Research and Educational Program (MAREP) under the Schlegel Research Institute in Aging, University of Waterloo, Waterloo, Ontario, Canada and Homewood Health Centre, Guelph, Ontario, Canada for all their support for my research. There are no conflict of interests.